# US 2020/0010492 A1 · Gpr84 receptor antagonist and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0010492 A1
- Document ID: US20200010492A1
- Status: Published application
- Kind: A1
- Application number: 16/490,837
- Filed: 2016-02-28
- Published: 2020-01-09
- Earliest claimed: 2016-02-28
- Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Applicants: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Inventors: Fajun NAN; Xin XIE; Linhai CHEN; Qing ZHANG; Yufeng XIAO; Hui YANG
- Web page: https://patentgrep.com/patent/US20200010492A1

## CPC

- C07F 9/09: Esters of phosphoric acids
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07F 9/117: with cycloaliphatic alcohols
- C07F 9/12: with hydroxyaryl compounds
- C07F 9/5535: {condensed with carbocyclic rings or ring systems}
- C07F 9/65517: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/65527: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/65539: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a GPR84 receptor antagonist and use thereof. The GPR84 receptor antagonist of the present invention has a structure as represented by formula (I), the definitions of R1, R2, R3, R4, L1, L2, L3, L4, L5, L6, Y, Z, and rings A, B, C, and D are as described in the description and claims. The GPR84 receptor antagonist of the present invention can competitively inhibit the activation of the receptor caused by an agonist of GPR84, and can be used in the preparation of a medicament for treating related diseases caused by high expression or high excitability of GPR84 receptor, the diseases including multiple sclerosis, inflammatory bowel disease, arthritis and the like.

## Claims

### Claim 1

A compound or a pharmaceutically acceptable salt having the structure of formula I,
wherein,
Y is O or S;
Z is H, or an ion of the following metal: Li, Na, K, Ca, Mg, Cu, Fe, Zn, Al, Mn, or a conjugated acid of the following base: NH3, arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, aminoglucose, histidine, hydroxycobalamin, isopropylamine, lysine, methyl glucosamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, trometamol;
L3 and L6 are each independently O, S, NH or CH2;
each of rings A, B, C, and D is independently a C6-C10 aromatic ring, a C3-C10 cycloalkane ring, a C3-C10 heterocycloalkane ring, or a C3-C10 heteroaryl ring;
R1, R2, R3, and R4 are each independently 1 to 4 substituents on rings A, B, C, and D, and each substituent is independently absent, hydroxyl, mercapto, amino, F, Cl, Br, I, —CrH2r-L7-CsH2s+1, —CrH2r—N(CtH2t+1)—CsH2s+1, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted C3-C10 heteroaryl, the above substitution means there is one or more substituents selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxyl, amino, —COOC1-C6 alkyl, —COOH; L7 is each independently 0, S, NH, each r is independently an integer of 0-6, each s is independently an integer of 0-6, and each t is independently an integer of 1-6;
L2 and L5 are each independently absent, CH, N;
L1 and L4 are each independently absent, CH, O, S, SO, SO2, —CH═CH—, CO, —C(═CH2)—, substituted or unsubstituted C1-C6 alkylidene, —NH—, —N(C1-C4 alkyl)-, C3-C6 cycloalkyl or C3-C6 heterocycloalkyl, said “substituted” means that there is one or more substituents selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy;
represents a single bond or a double bond.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein each of rings A, B, C and D is independently a benzene ring, a C3-C6 cycloalkane ring, a C3-C6 heterocycloalkane ring or a C3-C6 heteroaryl ring.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R1, R2, R3 and R4 are each independently one, two or three substituents on rings A, B, C and D, and each substituent is independently absent, substituted or unsubstituted C1-C4 alkyl, —CrH2r-L7-CsH2s+1, —CrH2r—N(CtH2t+1)—CsH2s+1, hydroxyl, mercapto, amino, F, Cl, Br, I; the above substitution means there is one or more substituents selected from the group consisting of halogen, hydroxyl, amino, —COOC1-C6 alkyl, —COOH; L7 is each independently O, S, NH, each r is independently an integer of 0-4, each s is independently an integer of 0-4, and each t is independently an integer of 1-4.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein L1 and L4 are each independently absent, CH, O, S, SO, SO2, —CH═CH—, CO, —C(═CH2)—, substituted or unsubstituted C1-C4 alkylidene, —NH—, —N(C1-C3 alkyl)-, C3-C6 cycloalkyl or C3-C6 oxa-cycloalkyl, said substitution means there is one or more substituents selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxyl.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein, a carbon attached to L3 and/or L6 and a carbon of ring B and/or ring D form —CH═CH— when L2 and/or L5 are absent;
a carbon attached to L3 and/or L6 and a carbon attached to L2 and/or L5 form —CH═CH— or —CH═N— when L2 and/or L5 are CH or N.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein said compound is:

### Claim 7 (depends on 1)

A method for preparing the compound according to claim 1, wherein the method comprises the following step:
reacting a compound of formula S1, a compound of formula S2 and a compound of formula S3 as starting materials to obtain the compound of formula I,
wherein R1, R2, R3, R4, L1, L2, L3, L4, L5, L6, Y, Z, ring A, B, C, and D are as defined in claim 1, and represents a single bond or a double bond;
X is F, Cl, Br or I.

### Claim 8 (depends on 1)

A method for preparing the compound according to claim 1, wherein the method comprises the following steps:
wherein R1, R2, R3, R4, L1, L2, L3, L4, L5, L6, Y, Z, ring A, B, C, and D are as defined in claim 1, and represents a single bond or a double bond;
X is F, Cl, Br or I.

### Claim 9 (depends on 1)

A pharmaceutical composition, comprising the compound or the pharmaceutically acceptable salt according to claim 1; and
a pharmaceutically acceptable carrier.

### Claim 10 (depends on 1)

Use of the compound or the pharmaceutically acceptable salt according to claim 1,
(i) for the preparation of a GPR84 antagonist;
(ii) as a GPR84 antagonist;
(iii) for the preparation of a medicament for the treatment of a related disease caused by hyper-excitability or high expression of GPR84 receptor.
